Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.54 |
| ▸ | BRAF | P15056 | 3/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19862479 | 0.93 | KMO (0.64) | KMOBRAFDRD3HCRTR1HCRTR2 | |
| SCHEMBL25340114 | 0.89 | KMO (0.48) | KMOBRAFDRD3HCRTR1HCRTR2 | |
| SCHEMBL30945941 | 0.89 | HTR2C (0.54) | KMOBRAFDRD3SIGMAR1 | |
| SCHEMBL29224145 | 0.89 | HTR2C (0.54) | KMOBRAFDRD3SIGMAR1 | |
| SCHEMBL4347071 | 0.83 | KMO (0.54) | KMODRD3HCRTR1HCRTR2SIGMAR1 | |
| SCHEMBL32688137 | 0.81 | KMT2A (0.46) | KMOBRAFDRD3HCRTR1HCRTR2 | |
| SCHEMBL2908064 | 0.80 | KMO (0.59) | KMOBRAFDRD3HDAC4HDAC2 | |
| SCHEMBL28767888 | 0.79 | KMO (0.39) | KMOBRAFDRD3OPRM1OPRD1 | |
| SCHEMBL10389972 | 0.79 | SMN1; SMN2 (0.54) | ATMMAPTSMN1; SMN2L3MBTL1GAA | |
| SCHEMBL9430916 | 0.79 | ATM (0.46) | KMODRD3ATMRIPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108929263-A | Aryl amide Kv2.1 inhibitor and preparation method thereof, pharmaceutical composition and purposes | 中国医学科学院药物研究所 | 2018-12-04 | — | — | CN | disclosed |
| EP-2927218-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-9725423-B2 | Tetrazolinone compound and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| CN-104822666-B | Terazololine-one compound and application thereof | 住友化学株式会社 | 2016-09-21 | — | — | CN | disclosed |
| CN-105503900-A | Prasugrel defluorinated impurity compound, and preparation method and application thereof | BEIJING PUDEKANGLI PHARMACEUTICAL TECH DEV CO LTD | 2016-04-20 | — | — | CN | disclosed |
| US-20150299146-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2927218-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-07 | — | — | EP | disclosed |
| CN-104822666-A | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL CO | 2015-08-05 | — | — | CN | disclosed |
| WO-2010131147-A1 | CYCLOBUTENEDIONE DERIVATIVES | PFIZER LIMITED (GB) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010131145-A1 | CYCLOBUTENEDIONE DERIVATIVES | PFIZER LIMITED (GB) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010131145-A1 | CYCLOBUTENEDIONE DERIVATIVES | PFIZER LIMITED (GB) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010131146-A1 | CYCLOBUTENEDIONE DERIVATIVES | PFIZER LIMITED (GB) | 2010-11-18 | — | — | WO | disclosed |
| EP-1740576-B1 | NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | PSEN2, SMN1; SMN2, OTC | KMO 532/4885BRAF 3420/4885DRD3 1385/4885 |
| US-20150299146-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | RTN3, CYCS, ATL3 | KMO 2005/4885BRAF 1251/4885DRD3 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.